Lyophilized PEG-Asparaginase Formulation for Stable Leukemia Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
L-asparaginase, a therapeutic enzyme for treating leukemia, faces challenges such as high clearance rate and potential immune response due to its protein nature, necessitating the development of a more stable and non-antigenic formulation.
Innovation Solution
A lyophilized polyalkylene oxide-asparaginase composition is developed, comprising a polyalkylene oxide group covalently linked to asparaginase, along with buffers, salts, and sugars, which is reconstituted with water for injection, providing stability and reduced immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If L-asparaginase is used as a protein therapeutic, then therapeutic activity is achieved, but high clearance rate and immune response occur
Solution Approach 1:
The patent applies composite materials by conjugating L-asparaginase enzyme with polyethylene glycol (PEG) polymer to create PEG-asparaginase. This composite structure combines the therapeutic function of the enzyme with the stabilizing and immunomodulating properties of PEG, resulting in reduced clearance rate, extended circulation half-life, and decreased immunogenicity while maintaining enzymatic activity.
Solution Approach 2:
The polyethylene glycol acts as an intermediary molecule between the immune system and the L-asparaginase enzyme. The PEG chain forms a steric barrier that prevents immune recognition of the enzyme, thereby reducing antibody formation and clearance while allowing the enzyme to maintain its catalytic function.
2Reliability
If L-asparaginase is used as a protein therapeutic, then therapeutic activity is achieved, but immune response is induced
Solution Approach 1:
The PEG-asparaginase composite reduces immunogenicity by incorporating PEG, which masks the enzyme's antigenic determinants. This composite structure decreases the formation of anti-asparaginase antibodies while preserving the enzyme's ability to hydrolyze L-asparagine, thereby maintaining therapeutic efficacy.
Solution Approach 2:
Polyethylene glycol serves as an intermediary that interferes with the interaction between the immune system and the L-asparaginase enzyme. The PEG chain creates a hydrophilic barrier that prevents immune cell recognition and antibody binding, reducing the harmful immune response while allowing the enzyme to function therapeutically.
3Stability of the object's composition
If lyophilized formulation is used, then storage stability is improved, but reconstitution process is required
Solution Approach 1:
The patent utilizes phase transitions by freeze-drying (lyophilizing) the PEG-asparaginase formulation to convert it from liquid to solid state for stable storage. The formulation includes excipients that protect the enzyme structure during freezing and drying phases. Before administration, the lyophilized powder is reconstituted with sterile water, transitioning back to liquid form while maintaining enzymatic activity and stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition maintains enzymatic activity and stability over extended periods, reducing immune response and clearance rate, making it suitable for treating neoplastic conditions like acute myeloid leukemia.
Implementation Method 1
a polyalkylene oxide-asparaginase, wherein the polyalkylene oxide-asparaginase comprises an asparaginase covalently linked to a polyalkylene oxide group
Implementation Method 2
wherein the lyophilized storage stable composition is capable of forming the composition described in the previous paragraph by reconstituting the lyophilized storage stable composition with water for injection (WFI)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Aspects of the invention include polyalkylene oxide-asparaginase compositions. In some instances, the composition is a lyophilized storage stable composition. In some instances, the lyophilized compositions include one or more of a buffer, a salt, and a sugar. Aspects of the invention further include methods of making the compositions. The compositions find use in a variety of applications, e.g., in the treatment of a neoplastic condition in a subject.